Loading company…
Meili Nanotechnology develops nanopore sequencing instruments and early cancer detection devices.
Established in 2017 and based in Shenzhen, China, Meili Nanotechnology develops nanopore early cancer detection devices and sells gene sequencing instruments and reagents. Its products include the MePore single-channel sequencing system, MeMob gene sequencers and multichannel microfluidic chips, covering immunological, microbiological, biochemical and molecular testing. In February 2023 the company closed a Series A+ round led by Antubio. It is at Series A stage.
Funding rounds, investors and people for this company come from licensed data. A free account shows the first rows of each section; an approved contribution opens every profile in full.
Sign in